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isoleucine alteration in the naturally occurring enzyme.6 A single
amino acid substitution not corresponding to any naturally
occurring b-lactamase was identified in the mutants derived
from OXA-10 (Table 1). Danel et al.4 also generated (with non-
hypermutable P. aeruginosa) an OXA-derived ESBL from R151
that does not correspond to a naturally occurring enzyme.
Although ceftazidime resistance has been associated with
hypermutability in clinical isolates of P. aeruginosa from chronic
lung infections2 it is not known whether these strains contain
ESBLs. Indeed on the basis of data reported here, we suggest
that hypermutable P. aeruginosa may not be the source of
those ESBLs found in clinical isolates of this organism. This
situation may reflect the relative ease by which derepression of
AmpC in P. aeruginosa provides a route for resistance to
expanded-spectrum b-lactams.
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Sir,
Enterobacter cloacae, Citrobacter freundii and Serratia
marcescens are important nosocomial pathogens. In Korea,
extended-spectrum b-lactamase (ESBL) prevalence in AmpC-
producing E. cloacae, C. freundii and S. marcescens is quite high
(10.9–23.6%), and these ESBL-producers show higher resistance
rates to aminoglycosides than do the ESBL-non-producers.1
While ribosomal protection mediated by methylation of 16S rRNA
has been known as a self-defense mechanism for aminoglycoside-
producing actinomycetes, it was not reported in other species
until 2003. However, a series of methylases have been identified
in several nosocomial pathogens, including Pseudomonas
aeruginosa,2 S. marcescens,3 Proteus mirabilis4 and Klebsiella
pneumoniae.5 The existence of these enzymes (RmtA, RmtB,
RmtC and ArmA) is of great concern because they are capable
of conferring an extraordinary high level of resistance (MIC >
512 mg/L) against most clinically important aminoglycosides, and
they were often associated with ESBLs.6
In the present study, a total of 413 consecutive, non-duplicate
isolates, including E. cloacae (158), C. freundii (126) and
S. marcescens (129), were collected during March–July 2003 at
11 university hospitals in Korea. The isolates were from wound
(37%), urine (35%), respiratory specimen (20%), blood (4%) and
body fluid (4%). The MICs of amikacin (8–512 mg/L) and
arbekacin (8–512 mg/L) were determined by an agar dilution
method in accordance with the CLSI guideline. The detection of
ESBL was based on the double disc synergy test (DDST) using
discs containing 30 mg of ceftazidime, cefotaxime, aztreonam and
cefepime. They were placed 2 cm from a disc containing
amoxicillin/clavulanic acid (20/10 mg) (BBL, Cockeysville,
MD, USA).
For the isolates that showed high-level resistance (MICs of
>512 mg/L) to amikacin or arbekacin, a search for the 16S rRNA
methylase genes (rmtA, rmtB, rmtC and armA) was performed by
PCR. The total DNAs were extracted from isolates by boiling and
the PCR was carried out with the Taq DNA polymerase (Takara
Shuzo, Shiga, Japan) and the following sets of primers: rmtA-F,
50-CTA GCG TCC ATC CTT TCC TC-30; rmtA-R, 50-TTT GCT
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TCC ATG CCC TTG CC-30; rmtB-F, 50-CCC AAA CAG ACC
GTA GAG GC-30; rmtB-R, 50-CTC AAA CTC GGC GGG CAA
GC-30; rmtC-F, 50-CGA AGA AGT AAC AGC CAA AG-30;
rmtC-R, 50-ATC CCA ACA TCT CTC CCA CT-30; armA-F, 50-
AGG TTG TTT CCA TTT CTG AG-30; armA-R, 50-TCT CTT
CCA TTC CCT TCT CC-30. Plasmids harbouring each gene were
used as positive controls. For the detection of the ESBL genes,
primers specific for blaTEM (TEM-F, 5
0-ATA AAA TTC TTG
AAG AAA-30; TEM-R, 50-GAC AGT TAC CAA TGC TTA
ATC-30), blaSHV (SHV-F, 50-TGG TTA TGC GTT ATA TTC
GCC-30; SHV-R, 50-GGT TAG CGT TGC CAG TGC T-30),
blaCTX-M (CTX-M-F, 5
0-CGC TTT GCG ATG TGC AG-30; CTX-
M-R, 50-ACC GCG ATA TCG TTG GT-30), blaCTX-M-9 (CTX-
M-9-F, 50-CGC TTT ATG CGC AGA CGA-30; CTX-M-9-R,
50-GAT TCT CGC CGC TGA AGC-30) and blaPER-1 (PER-1-F,
50-AAT TTG GGC TTA GGG CAG AA-30; PER-1-R, 50-ATG
AAT GTC ATT ATA AAA GC-30) were used. PCR products
were purified with a QIAquick PCR purification kit (QIAGEN,
Hilden, Germany) and sequenced on a 3730 DNA analyser
(Applied Biosystems, Foster City, CA, USA). The nucleotide and
deduced protein sequences were analysed with software available
from the National Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov).
Of the total 413 isolates, 58 were resistant to amikacin, and the
majority (49/58, 84.5%) of these 58 isolates showed high-level
resistance (MIC > 512 mg/L) to both amikacin and arbekacin.
One E. cloacae isolate was highly resistant to arbekacin (MIC >
512 mg/L), but it was susceptible to amikacin (16 mg/L). The
frequency of the high-level resistance to amikacin or arbekacin
was 9.5% (15/158), 10.3% (13/126) and 17.1% (22/129) for
E. cloacae, C. freundii and S. marcescens isolates, respectively,
and almost all of them (13 E. cloacae, 12 C. freundii and 21
S. marcescens isolates) harboured the armA gene. One C. freundii
isolate harboured the rmtB gene. The 16S rRNA methylase-
harbouring isolates were isolated from nine hospitals distribu-
ted nationwide. All of them were highly resistant to both
arbekacin and amikacin. None harboured an rmtA or rmtC gene.
The ESBL production rate was significantly higher in 16S rRNA
methylase-producers (100%, 76.9% and 66.7% among E. cloacae,
C. freundii and S. marcescens, respectively), compared with 16S
rRNA methylase-non-producers (25.0%, 12.4% and 10.2%,
respectively) (P = 0.002, P < 0.001 and P < 0.001, respectively).
Most of the ArmA producers co-harboured various ESBLs
(CTX-M-3, CTX-M-9, CTX-M-14, TEM-52 and SHV-12),
among which CTX-M-3 was the most common (Table 1).
This finding corroborates the previous reports that the
armA was frequently associated with blaCTX-M and they were
co-transferred by conjugation.6,7 Although only one isolate
harboured the rmtB gene in the present study, it also harboured
CTX-M-14; this coincides with the report by Yan et al.6 where six
out of the seven rmtB-positive isolates harboured CTX-M-14. In
Korean medical practice, arbekacin is only rarely used for the
treatment of methicillin-resistant Staphylococcus aureus. Never-
theless, the prevalence of high-level resistance to amikacin and
arbekacin was similarly high, suggesting that armA can confer
resistance to arbekacin as in other 16S rRNA methylases.2,3
In conclusion, the armA gene is widespread in Korean
isolates of E. cloacae, C. freundii and S. marcescens, and an
rmtB producer was also found. Given the multiresistance in these
isolates, prudent antibiotic use, accurate detection of this
resistance and strict infection control are urgently needed to
prevent the spread of these organisms.
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Table 1. Distribution of ESBLs among 16S rRNA
methylase-producing E. cloacae, C. freundii and S. marcescens
E. cloacae
(13)
C. freundii
(13)
S. marcescens
(21)
ESBL producers 13 10 14
CTX-M-3 9 4 12
CTX-M-9 0 1 0
CTX-M-14 0 1 (rmtB) 1
TEM-52 1 0 0
SHV-12 2 1 1
PER-1 0 0 0
undetermined 1 3 0
Correspondence
908
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on June 18, 2014
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
